These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 324695)

  • 21. [Clinical--pharmacological aspects of treatment with sodium di-n-propylacetate].
    Wulff K; Flachs H; Würtz-Jørgensen A; Gram L
    Ugeskr Laeger; 1977 May; 139(18):1059-64. PubMed ID: 324057
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bioavailability of sodium valproate is modified by diet].
    Loiseau P; Cenraud B; Morselli PL; Brachet-Liermain A
    Nouv Presse Med; 1979 Jun; 8(26):2202-3. PubMed ID: 382109
    [No Abstract]   [Full Text] [Related]  

  • 23. Metabolism of valproate sodium in rabbit, rat, dog, and man.
    Ferrandes B; Eymard P
    Epilepsia; 1977 Jun; 18(2):169-82. PubMed ID: 326545
    [No Abstract]   [Full Text] [Related]  

  • 24. Absorption rate and bioavailability of valproic acid and its sodium from rectal dosage forms.
    Moolenaar F; Greving WJ; Huizinga T
    Eur J Clin Pharmacol; 1980 Apr; 17(4):309-15. PubMed ID: 6772450
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans.
    Bialer M; Friedman M; Dubrovsky J; Raz I; Abramsky O
    Biopharm Drug Dispos; 1985; 6(4):401-11. PubMed ID: 3936558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of valproic acid--1988.
    Zaccara G; Messori A; Moroni F
    Clin Pharmacokinet; 1988 Dec; 15(6):367-89. PubMed ID: 3149565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy testing of valproic acid compared to ethosuximide in monkey model: I. Dosage regimen design in the presence of diurnal oscillations.
    Levy RH; Lockard JS; Patel IH; Lai AA
    Epilepsia; 1977 Jun; 18(2):191-203. PubMed ID: 406138
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study.
    Schapel GJ; Beran RG; Doecke CJ; O'Reilly WJ; Reece PA; Rischbieth RH; Sansom LN; Stanley PE
    Eur J Clin Pharmacol; 1980 Jan; 17(1):71-7. PubMed ID: 6768573
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril.
    Johannessen SI; Henriksen O
    Acta Neurol Scand; 1979 Dec; 60(6):371-4. PubMed ID: 121513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Differentiation of the degree of bioavailability of peroral drug forms of tetracycline hydrochloride in experiments on laboratory animals].
    Zak AF; Ermolova OB
    Antibiotiki; 1976 Feb; 21(2):151-5. PubMed ID: 1275466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of sodium valproate on plasma protein binding of diphenylhydantoin.
    Patsalos PN; Lascelles PT
    J Neurol Neurosurg Psychiatry; 1977 Jun; 40(6):570-4. PubMed ID: 20483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of valproic acid.
    Gugler R; von Unruh GE
    Clin Pharmacokinet; 1980; 5(1):67-83. PubMed ID: 6767575
    [No Abstract]   [Full Text] [Related]  

  • 34. Bioavailability of valproic acid under fasting/nonfasting regimens.
    Chun AH; Hoffman DJ; Friedmann N; Carrigan PJ
    J Clin Pharmacol; 1980 Jan; 20(1):30-6. PubMed ID: 6766956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steady-state valproate pharmacokinetics during long term therapy.
    Eadie MJ; Heazlewood V; McKauge L; Tyrer JH
    Clin Exp Neurol; 1983; 19():183-91. PubMed ID: 6439443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of valproate after gastric and direct intestinal administration in rats.
    Yeomans ND; Vajda FJ; Baldas J
    Clin Exp Pharmacol Physiol; 1982; 9(2):173-7. PubMed ID: 6813007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed toxicity following ingestion of enteric-coated divalproex sodium (Epival).
    Brubacher JR; Dahghani P; McKnight D
    J Emerg Med; 1999; 17(3):463-7. PubMed ID: 10338240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of the analysis and interpretation of bioavailability studies in man.
    Wagner JG
    Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of valproic acid in young and elderly subjects.
    Bryson SM; Verma N; Scott PJ; Rubin PC
    Br J Clin Pharmacol; 1983 Jul; 16(1):104-5. PubMed ID: 6411107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.